Bladder cancer tumor marker, antibody and use thereof
AssigneeInstitute of Biophysics, Chinese Academy of Sciences
InventorsChong Li, Zusen Fan, Honglian Zhang, Zhonghua Dai, Haidong Tang, Jun Chen
Life of this patent
Estimating the term…
Abstract
Provided in the present invention are an aberrantly glycosylated integrin, AG-α3β1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-α3β1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.
Claims8
A binding molecule directed agains an aberrantly glycosylated integrin AG-α3β1,
- wherein the AG-α3β1 comprises a carbohydrate [3OSO3]Galβ1-4(Fucα1-3)[6OSO3]GlcNAc as an antigenic epitope having a structure of:
- wherein the binding molecule recognises or binds to the carbohydrate and is an anti-AG-α3β1 monoclonal antibody BCMab1 secreted by a hydridoma call line deposited as CGMCC No. 3845.
A kit for detecting bladder cancer, comprising a binding molecule directed against an aberrantly glycosylated intergrin AG-α3β1;
- and optionally another reagent for detecting bladder cancer,
- wherein the binding molecule is optionally conjugated with a substance selected from the group consisting of a biological marker, an antitumor drug, a toxin, and a radioactive agent,
- wherein the AG-α3β1 comprises a carbohydrate [3OSO3]Galβ1-4(Fucα1-3)[6OSO3]GlcNAc as an antigenic epitope having a structure of:
- wherein the binding molecule recongnizes or binds to the carbohydrate and is an anti-AG-α3β1 monoclonal antibody BCMab1 secreted by a hybridoma cell line deposited as CGMCC No. 3845.
A hybridoma cell line secreting antibody BCMab1 directed against integrin α3β1 of human bladder cancer, wherein the hybridoma cell line is deposited as CGMCC No. 3845.
Dependencies are inferred from the claim text.